‘Exciting clinical and commercial opportunity’: Prescient
Australian biotechnology company Prescient Therapeutics is enrolling up to 12 new patients for the next...
Australian biotechnology company Prescient Therapeutics is enrolling up to 12 new patients for the next...
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has announced the opening of enrolment...
Prescient Therapeutics Ltd (ASX:PTX)'s Steven Yatomi-Clarke explains how the company is combatting the leading, global...
Prescient Therapeutics (PTX) has opened patient enrolments for an expanded phase 1B trial of its...
Strong early indicators for the PTX-100 treatment give Prescient multiple pathways to market, as it...
Prescient Therapeutics (ASX: PTX) has begun recruiting for expanded clinical trial evaluating its drug PTX-100 in...
Cancer results from the mutation of normal cells to tumour cells because of interaction between...
Cancer-fighting biotech company Prescient Therapeutics has continued to hit its clinical and development milestones in...
ASX-listed biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) is leaving no stone unturned as it progresses towards...
Investors have plenty of exciting updates to look forward as PTX advances clinical trials and...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.